No material impact of US court order, says Sun Pharmaceuticals (spot)

Pharmaceutical major Sun Pharmaceuticals has said a US court order in a class action lawsuit against its US subsidiary will not have a material impact on its operations.

The company made this submission in its response to the stock exchange today following reports that a US appeal court had upheld a local district court order against its subsidiary Caracao Pharmaceutical Laboratories. The suit was initiated by an employees of Caracao who alleged that they were terminated in 2009 without mandatory 60 day notice under law.

The employees had complained that the company had failed to give them a notice while closing a drug manufacturing facility in Michigan, US. Caracao had cited mass seizure of its products by the Food and Drugs Administration (USFDA) as an unforeseeable business circumstance and sought excuse from complying with rules which require it to give 60-day notice but the US court refused to accept the plea.

"We confirm that this is regarding a decision from the 6th US Circuit Court of Appeals in a class action lawsuit by some former employees of our US subsidiary company in US following the shut down of company's subsidiary's Michigan facility," Sun Pharmaceuticals said in a stock exchange notification.


Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel